» Articles » PMID: 35566093

Development of Neuropeptide Y and Cell-Penetrating Peptide MAP Adsorbed Onto Lipid Nanoparticle Surface

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2022 May 14
PMID 35566093
Authors
Affiliations
Soon will be listed here.
Abstract

Functionalization of nanoparticles surfaces have been widely used to improve diagnostic and therapeutic biological outcome. Several methods can be applied to modify nanoparticle surface; however, in this article we focus toward a simple and less time-consuming method. We applied an adsorption method on already formulated nanostructured lipid carriers (NLC) to functionalize these nanoparticles with three distinct peptides sequences. We selected a cell-penetrating peptide (CPP), a lysine modified model amphipathic peptide (Lys(N)-MAP), CPP/drug complex, and the neuropeptide Y. The aim of this work is to evaluate the effect of several parameters such as peptide concentration, different types of NLC, different types of peptides, and incubation medium on the physicochemical proprieties of NLC and determine if adsorption occurs. The preliminary results from zeta potential analysis indicate some evidence that this method was successful in adsorbing three types of peptides onto NLC. Several non-covalent interactions appear to be involved in peptide adsorption with the possibility of three adsorption peptide hypothesis that may occur with NLC in solution. Moreover, and for the first time, in silico docking analysis demonstrated strong interaction between CPP MAP and NPY Y1 receptor with high score values when compared to standard antagonist and NPY.

Citing Articles

Applications of cell penetrating peptide-based drug delivery system in immunotherapy.

Du J, Zhang R, Jiang S, Xiao S, Liu Y, Niu Y Front Immunol. 2025; 16:1540192.

PMID: 39911386 PMC: 11794548. DOI: 10.3389/fimmu.2025.1540192.


CHARMM-GUI : Past, Current, and Future Developments and Applications.

Feng S, Park S, Choi Y, Im W J Chem Theory Comput. 2023; 19(8):2161-2185.

PMID: 37014931 PMC: 10174225. DOI: 10.1021/acs.jctc.2c01246.


Approaches for evaluation of novel CPP-based cargo delivery systems.

Porosk L, Langel U Front Pharmacol. 2022; 13:1056467.

PMID: 36339538 PMC: 9634181. DOI: 10.3389/fphar.2022.1056467.


A Second Life for MAP, a Model Amphipathic Peptide.

Silva S, Kurrikoff K, Langel U, Almeida A, Vale N Int J Mol Sci. 2022; 23(15).

PMID: 35955457 PMC: 9368858. DOI: 10.3390/ijms23158322.

References
1.
Silva S, Marto J, Goncalves L, Almeida A, Vale N . Formulation, Characterization and Evaluation against SH-SY5Y Cells of New Tacrine and Tacrine-MAP Loaded with Lipid Nanoparticles. Nanomaterials (Basel). 2020; 10(10). PMC: 7589787. DOI: 10.3390/nano10102089. View

2.
Magni P, Beretta E, Scaccianoce E, Motta M . Retinoic acid negatively regulates neuropeptide Y expression in human neuroblastoma cells. Neuropharmacology. 2000; 39(9):1628-36. DOI: 10.1016/s0028-3908(99)00231-2. View

3.
Aggarwal P, Hall J, McLeland C, Dobrovolskaia M, McNeil S . Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev. 2009; 61(6):428-37. PMC: 3683962. DOI: 10.1016/j.addr.2009.03.009. View

4.
Wang E, Wang A . Nanoparticles and their applications in cell and molecular biology. Integr Biol (Camb). 2013; 6(1):9-26. PMC: 3865110. DOI: 10.1039/c3ib40165k. View

5.
Decressac M, Wright B, Tyers P, Gaillard A, Barker R . Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease. Exp Neurol. 2010; 226(1):24-32. DOI: 10.1016/j.expneurol.2010.07.022. View